<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:f48f892a-72c7-43be-913e-ca703a665f92,g:21a73786-5f4c-4ea0-b1c3-eb2458f62d05,d:0d6a8b41eaa346919cda84f8f4c6444b--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrtx-20220505</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xMy9mcmFnOmFkOTBlMDU5Mzc3YTQwZjhhMjQwYzkwMGI4MzM0ZjgxL3RhYmxlOjNlYzNhOTg5ODFlNDRhNTA5MmE5ZWNmYmY2MGU5MWViL3RhYmxlcmFuZ2U6M2VjM2E5ODk4MWU0NGE1MDkyYTllY2ZiZjYwZTkxZWJfMi0xLTEtMS01NjMwOQ_f30c2701-12fd-4919-9fb9-23769123ee15">0000875320</ix:nonNumeric><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xMy9mcmFnOmFkOTBlMDU5Mzc3YTQwZjhhMjQwYzkwMGI4MzM0ZjgxL3RhYmxlOjNlYzNhOTg5ODFlNDRhNTA5MmE5ZWNmYmY2MGU5MWViL3RhYmxlcmFuZ2U6M2VjM2E5ODk4MWU0NGE1MDkyYTllY2ZiZjYwZTkxZWJfMy0xLTEtMS01NjMwOQ_66959895-3edd-460e-b0ea-c4affdf75e00">VERTEX PHARMACEUTICALS INC / MA</ix:nonNumeric><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xMy9mcmFnOmFkOTBlMDU5Mzc3YTQwZjhhMjQwYzkwMGI4MzM0ZjgxL3RhYmxlOjNlYzNhOTg5ODFlNDRhNTA5MmE5ZWNmYmY2MGU5MWViL3RhYmxlcmFuZ2U6M2VjM2E5ODk4MWU0NGE1MDkyYTllY2ZiZjYwZTkxZWJfNi0xLTEtMS01NjMwOQ_e6232549-5641-4774-bf62-aacc2e314dc9">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrtx-20220505.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0d6a8b41eaa346919cda84f8f4c6444b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:232%">FORM <ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjE5_cd776b38-92cc-4620-9ba8-dc869c8b8bc9">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18yMjU_f93d0680-c220-41d9-9c8f-d252f2f42f8c">May 5, 2022</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:144%">Vertex Pharmaceuticals Incorporated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGFibGU6MjNlNDUyYzMxM2U2NDZlN2JjN2I4ZjJiYjVmMmJlODQvdGFibGVyYW5nZToyM2U0NTJjMzEzZTY0NmU3YmM3YjhmMmJiNWYyYmU4NF8wLTAtMS0xLTU2MzA5_6a8191a8-30a4-40d8-b495-0cccf8b12604">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGFibGU6MjNlNDUyYzMxM2U2NDZlN2JjN2I4ZjJiYjVmMmJlODQvdGFibGVyYW5nZToyM2U0NTJjMzEzZTY0NmU3YmM3YjhmMmJiNWYyYmU4NF8wLTEtMS0xLTU2MzA5_b8c616d3-d09f-45ed-aa35-43d4c01327a5">000-19319</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGFibGU6MjNlNDUyYzMxM2U2NDZlN2JjN2I4ZjJiYjVmMmJlODQvdGFibGVyYW5nZToyM2U0NTJjMzEzZTY0NmU3YmM3YjhmMmJiNWYyYmU4NF8wLTItMS0xLTU2MzA5_52c7b5b2-f2dc-4b66-b549-1ad42d53c56b">04-3039129</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjI3_d2266f84-e67c-4fee-a928-2a5316ea7a86">50 Northern Avenue</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjI4_c87cbc10-56d4-4b29-9d70-e91510e5d74c">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjIw_89103112-2074-4c88-8041-fc33b7de4856">Massachusetts</ix:nonNumeric>  <ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjI5_1efb3c94-982c-4fd8-b107-90912080d4f1">02210</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:144%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjIx_5a3b262a-8a50-4689-902d-8404848b9bbf">617</ix:nonNumeric>) <ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjIy_5dbf07c4-f26a-4fa2-9623-9f25d9ac6aaa">341-6100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjMw_82506cca-37dd-4b7e-baed-43a120ceff9d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjIz_c0a51127-f615-4b46-af94-6ecae1fca6ef">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjI0_b882f9b1-85fe-4fec-bc89-29ca049be1a8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjI1_efd9cac4-dd77-44aa-827c-3e51ab202465">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGFibGU6ZmFlMjU3NWU3NWJlNDc5MDk1MWFhODUwMzQ1NDY5M2UvdGFibGVyYW5nZTpmYWUyNTc1ZTc1YmU0NzkwOTUxYWE4NTAzNDU0NjkzZV8yLTAtMS0xLTU2MzA5_a3ed60e9-964a-43cf-8033-431ed2c8f3cf">Common Stock, $0.01 Par Value Per Share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGFibGU6ZmFlMjU3NWU3NWJlNDc5MDk1MWFhODUwMzQ1NDY5M2UvdGFibGVyYW5nZTpmYWUyNTc1ZTc1YmU0NzkwOTUxYWE4NTAzNDU0NjkzZV8yLTItMS0xLTU2MzA5_89e35f6c-8820-48ff-945e-8c45aa4b4c9a">VRTX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGFibGU6ZmFlMjU3NWU3NWJlNDc5MDk1MWFhODUwMzQ1NDY5M2UvdGFibGVyYW5nZTpmYWUyNTc1ZTc1YmU0NzkwOTUxYWE4NTAzNDU0NjkzZV8yLTQtMS0xLTU2MzA5_7dc223dc-8974-41cc-a25a-fbea089da151">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia26b6ac311d247098c195998caa13a0b_D20220505-20220505" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjBkNmE4YjQxZWFhMzQ2OTE5Y2RhODRmOGY0YzY0NDRiL3NlYzowZDZhOGI0MWVhYTM0NjkxOWNkYTg0ZjhmNGM2NDQ0Yl8xL2ZyYWc6MjNjY2EwODJjMjc4NGIwNDk2NDY5NWIzMmZiNTExZGMvdGV4dHJlZ2lvbjoyM2NjYTA4MmMyNzg0YjA0OTY0Njk1YjMyZmI1MTFkY18xNjI2_a5e9e7fa-4ee6-488c-8824-44a29a5f3cab">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0d6a8b41eaa346919cda84f8f4c6444b_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Item 2.02.&#160; Results of Operations and Financial Condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">On May&#160;5, 2022, we issued a press release in which we reported our consolidated financial results for the three months ended March 31, 2022.  A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:142%">Starting in the first quarter of 2022, we no longer exclude research and development charges resulting from upfront or contingent milestone payments in connection with collaborations, asset acquisitions and/or licensing of third-party intellectual property rights from our Non-GAAP measures. Non-GAAP net income and Non-GAAP net income per diluted common share for each quarter of 2021 and the year ended December 31, 2021 have been recast to reflect this change. The recast presentation is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">The information set forth in Exhibits 99.1 and 99.2 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div id="i0d6a8b41eaa346919cda84f8f4c6444b_7"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">&#160;&#160;&#160;&#160;(d)  Exhibits</span></div><div><span><br/></span></div><div style="padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.064%"><tr><td style="width:1.0%"></td><td style="width:8.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-991_q12022.htm">Press Rele</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-991_q12022.htm">a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-991_q12022.htm">se Dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-991_q12022.htm">May 5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-991_q12022.htm">, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex-992_reconciliationofrep.htm">Reconciliation of Reported to Revised GAAP to Non-GAAP Net Income for each quarter of 2021 and the year ended December 31, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File &#8212; the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0d6a8b41eaa346919cda84f8f4c6444b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#160; </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VERTEX PHARMACEUTICALS INCORPORATED</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:99pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:  May&#160;5, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Joy Liu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Joy Liu</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "vrtx-20220505.htm", "description": "8-K", "secsgml_size_bytes": 35075}]
{"company-data": {"conformed-name": "VERTEX PHARMACEUTICALS INC / MA", "cik": "0000875320", "assigned-sic": "2834", "irs-number": "043039129", "state-of-incorporation": "MA", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19319", "film-number": "22896103"}, "business-address": {"street1": "50 NORTHERN AVENUE", "city": "BOSTON", "state": "MA", "zip": "02210", "phone": "6173416393"}, "mail-address": {"street1": "50 NORTHERN AVENUE", "city": "BOSTON", "state": "MA", "zip": "02210"}}
vrtx-20220505
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 5, 2022
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
000-19319
04-3039129
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
50 Northern Avenue
Boston
,
Massachusetts
02210
(Address of principal executive offices) (Zip Code)
(
617
)
341-6100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.  Results of Operations and Financial Condition.
On May 5, 2022, we issued a press release in which we reported our consolidated financial results for the three months ended March 31, 2022.  A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Starting in the first quarter of 2022, we no longer exclude research and development charges resulting from upfront or contingent milestone payments in connection with collaborations, asset acquisitions and/or licensing of third-party intellectual property rights from our Non-GAAP measures. Non-GAAP net income and Non-GAAP net income per diluted common share for each quarter of 2021 and the year ended December 31, 2021 have been recast to reflect this change. The recast presentation is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.
The information set forth in Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.  Financial Statements and Exhibits.
(d)  Exhibits
Exhibit
Description of Document
99.1
Press Rele
a
se Dated
May 5
, 2022.
99.2
Reconciliation of Reported to Revised GAAP to Non-GAAP Net Income for each quarter of 2021 and the year ended December 31, 2021
104
Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date:  May 5, 2022
/s/ Joy Liu
Joy Liu
Senior Vice President, General Counsel